Cyproterone acetate: new advice to minimise risk of meningioma

Risk of meningioma with cyproterone acetate increases with increasing cumulative dose.

Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents

Remain vigilant for signs and symptoms of bleeding complications during treatment with DOACs (apixaban, dabigatran, edoxaban, rivaroxaban), especially in patients with increased bleeding risks.

Letters and drug alerts sent to healthcare professionals in May 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Posted on the UK MHRA website on 29 June 2020